Tiotropium for asthma: A summary of current guidelines and a case study.

Abstract

The long-acting muscarinic antagonist tiotropium received an indication for the treatment of asthma from the FDA in 2015. This paper summarizes much of the published findings on tiotropium and asthma and explores the heterogeneity of the asthma population vis-à-vis recent changes in guidelines for management of COPD. The accompanying case study provides an illustration of how tiotropium might be added to a patient's regimen appropriately. Tiotropium has been shown in many studies to be beneficial to patients with asthma as an add-on medication. It should be considered as an agent by the clinician managing patients with both allergic and non-allergic asthma.